TG Therapeutics announced two additional data presentations from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI in patients with relapsing forms of multiple sclerosis, at the 2024 American Academy of Neurology, AAN, annual meeting, being held in Denver, Colorado. Michael Weiss, Chief Executive Officer and Chairman of TG Therapeutics stated “The data presented this week during the AAN annual meeting emphasizes our commitment to research and the multiple sclerosis community. We look forward to continuing to evaluate date from the ULTIMATE Phase 3 trials and presenting additional exploratory data throughout the year.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TGTX:
- TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis
- TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
- TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
- TG Therapeutics presents data from ULTIMATE I & II, ENHANCE trials
- TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
